

Kelly L Hayward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/533724/publications.pdf>

Version: 2024-02-01

34
papers

605
citations

623734

14
h-index

642732

23
g-index

35
all docs

35
docs citations

35
times ranked

716
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards collaborative management of non-alcoholic fatty liver disease: a "real-world" pathway for fibrosis risk assessment in primary care. <i>Internal Medicine Journal</i> , 2022, 52, 1749-1758.	0.8	3
2	Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. <i>Hepatology Communications</i> , 2022, 6, 728-739.	4.3	20
3	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. <i>Diabetic Medicine</i> , 2022, 39, e14799.	2.3	8
4	Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. <i>BMC Health Services Research</i> , 2022, 22, 487.	2.2	2
5	Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 3281-3282.	4.3	1
6	Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis. <i>Journal of Hepatology</i> , 2022, 77, 1219-1221.	3.7	6
7	Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	9
8	Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis. <i>JGH Open</i> , 2021, 5, 133-142.	1.6	8
9	The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. <i>Hepatology Communications</i> , 2021, 5, 891-905.	4.3	8
10	Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000572.	2.7	19
11	Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 715-716.	4.3	0
12	Managing medicines in alcohol-associated liver disease: a practical review. <i>Australian Prescriber</i> , 2021, 44, 96-106.	1.0	3
13	Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. <i>Pharmaceuticals</i> , 2021, 14, 1207.	3.8	1
14	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 710-718.e4.	4.4	10
15	Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 45-57.	3.3	24
16	ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000485.	2.7	21
17	Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. <i>Internal Medicine Journal</i> , 2020, 50, 1142-1146.	0.8	10
18	Improving Medication-Related Outcomes in Chronic Liver Disease. <i>Hepatology Communications</i> , 2020, 4, 1562-1577.	4.3	14

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. <i>Hepatology Communications</i> , 2020, 4, 518-526.	4.3	12
20	<p>Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 599-611.	1.8	18
21	Reply. <i>Hepatology Communications</i> , 2019, 3, 1283-1284.	4.3	0
22	Medicationâ€Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. <i>Hepatology Communications</i> , 2019, 3, 620-631.	4.3	33
23	Underappreciation of nonâ€alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. <i>Internal Medicine Journal</i> , 2018, 48, 144-151.	0.8	80
24	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and Atâ€Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018, 2, 897-909.	4.3	54
25	Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 799-804.	2.3	10
26	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , 2017, 47, 429-435.	0.8	21
27	Optimising care of patients with chronic disease: patientâ€oriented education may improve disease knowledge and selfâ€management. <i>Internal Medicine Journal</i> , 2017, 47, 952-955.	0.8	23
28	Multimorbidity and polypharmacy in diabetic patients with NAFLD. <i>Medicine (United States)</i> , 2017, 96, e6761.	1.0	39
29	Advances in the treatment of chronic liver diseases â€ implications for pharmacy practice from a gastroenterology conference. <i>Journal of Pharmacy Practice and Research</i> , 2017, 47, 483-485.	0.8	0
30	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	1.9	17
31	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 339.	1.6	12
32	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7321-7331.	3.3	25
33	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 210-222.	2.4	69
34	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. <i>BMC Gastroenterology</i> , 2016, 16, 114.	2.0	25